Olema Pharmaceuticals logo

Olema Pharmaceuticals

OLMA | NASDAQ
Chart Builder DCF Calculator
$7.36
-$0.20 (-2.65%)
At close: Nov 16, 2026, 4:00 PM ET
$7.36
$0.00 (0.00%)
After-hours: Nov 16, 2026, 5:54 PM ET
-2.65%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
26.2
+1.5 pts
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #894/1021 (Top 88%)

Key Statistics

Market Data

Market Cap $744.04M
1D Range
7.08 7.73
52W Range
6.41 35.83

Valuation (TTM)

PE -3.11
PB 2.02
EV/EBITDA -1.39

Valuation (NTM)

Forward PE N/A
Forward PEG -0.08
Price Target $25.00
Loading financial charts...

Profile

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. H...

Sector Healthcare
Industry Biotechnology
Employees 150
IPO Date Nov 19, 2020
Fiscal Year January - December

Latest News

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

3 months ago · benzinga.com

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

6 months ago · globenewswire.com

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

6 months ago · globenewswire.com

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology to Participate in Upcoming Investor Conferences

6 months ago · globenewswire.com

Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

7 months ago · globenewswire.com

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

7 months ago · globenewswire.com

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

8 months ago · zacks.com

Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

8 months ago · fool.com

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

8 months ago · globenewswire.com

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

8 months ago · businesswire.com

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

Earnings

Next Earnings
Mar 15, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$25.00
Upside
+239.67%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.